Develops and manufactures off-patent branded pharmaceuticals, including branded generics and over-the-counter drugs. Now — the numbers.
This is an established company with proven profits.
Average growth of 5% a year over the last 4 years. Every year shown ended in profit.
The gap is $984.5M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 15.4× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
It pays out $1.01 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.